Article
BPC-157 vs TB-500: Differences & Research Comparison
See where the names, structures, and evidence for BPC-157 and TB-500 differ.
By Amrita Peptides · Updated
BPC-157 and TB-500 are two of the most frequently compared research peptides, and they are often referenced together in preclinical tissue-repair literature. They are not the same compound, though: they differ in origin, sequence, and how they are studied. This article compares them for research identification only and makes no claims about human use, safety, or benefit.
Quick comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Type | 15-amino-acid pentadecapeptide | Synthetic fragment related to thymosin beta-4 |
| Origin | Derived from a gastric protein fragment | Corresponds to an active region of thymosin beta-4 |
| CAS number | 137525-51-0 | 885340-08-9 |
| Form supplied | Lyophilised powder | Lyophilised powder |
| Research context | Gastric, tissue-response and connective-tissue models | Cell migration and tissue-repair models |
| Often studied with | TB-500, bacteriostatic water | BPC-157, bacteriostatic water |
Origin and identity
BPC-157 is a pentadecapeptide — 15 amino acids — investigated in a range of preclinical models. TB-500 is a synthetic peptide corresponding to an active region of the protein thymosin beta-4, and it is important not to conflate the fragment with the full native protein when reading the literature.
Because they arise from different proteins and have different sequences, they are distinct research references. Identify each listing by its stated name and product option rather than assuming equivalence; retail naming around TB-500 can vary between suppliers.
Why they are compared
Both peptides appear in preclinical research on tissue response and connective-tissue models, so they are frequently discussed side by side. That overlap in research context — not any established outcome — is why the two are often paired in discussion. This comparison does not recommend combined use, and nothing here should be read as evidence of efficacy for any use.
Handling and stability in Thailand
Do not assume that two peptides share a solvent, temperature range, or post-reconstitution shelf life. Use product-specific evidence or a validated protocol; the laboratory reconstitution guide and Thailand storage guide explain the compatibility and excursion questions to document.
Comparing the listings
The BPC-157 and TB-500 pages show their respective options and prices. Review each as a separate research material and use a qualified protocol to determine what, if anything, belongs in a study design.
Frequently asked questions
What if a TB-500 source actually discusses full-length thymosin beta-4?
Do not treat the terms as interchangeable. Check the sequence and material used in the paper: findings for the 43-amino-acid native protein cannot automatically be assigned to a shorter commercial fragment.
Can matching a CAS number distinguish BPC-157 from TB-500?
It can clarify which named structure a listing intends to describe, but a registry number is a catalogue identifier rather than evidence about the contents of a physical vial.
What should I do when a paper does not state the peptide sequence?
Treat the identity as unresolved for comparison purposes. Look for supplementary methods, supplier information, or cited synthesis details before mapping the findings to a listed product.
Does studying the peptides in related models justify combining them?
No. Overlapping research context is not evidence that a combination is appropriate, safe, or effective, and this comparison does not provide a combined protocol.
For laboratory research use only. Not for human or veterinary use.